The U.S. Ambulatory Surgery Center Market, estimated at USD 72.58 Bn in 2025, is expected to exhibit a CAGR of 5.2% and reach USD 103.5 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Key market players are engaged in adoption of growth strategies such as partnership to bring patient-centered and high-quality care to more communities, and this is expected to drive the market growth. For instance, on February 8, 2023, United Surgical Partners International (USPI), the ambulatory surgery platform, and a subsidiary of Tenet Healthcare, and Providence, a not-for-profit health system serving the Western U.S., announced that both companies has signed a new development agreement that will increase access to ambulatory surgical services across many communities.
U.S. Ambulatory Surgery Center Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets.
COVID-19 had a positive impact on the U.S. ambulatory surgery center market. The lack of hospital capacity due to the COVID-19 accelerated the expansion of ambulatory surgery center. Moreover, before the pandemic, ambulatory surgery centers and non-operative anesthesia practices typically obtained supplies from a limited number of vendors in countries with low labor costs and kept minimal excess inventory to reduce costs.
For instance, article published by National Center for Biotechnology Information (NCBI) in July, 2021, impact on treatment of Rhinology has been greatly affected by COVID-19. Personal care in the office setting and surgical treatment of sinonasal and skull base disease have made dramatic advances. Advanced personal protective equipment is used in only half of the potentially aerosol-generating procedures, an area where additional training is needed. New approaches such as virtual appointments and care testing should be considered to facilitate care.